A Study of Safety and Tolerability in Subjects With Schizophrenia
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This is an inpatient, open-label, multiple-dose, multicenter study to evaluate the safety and
tolerability of LY2140023 given at doses expected to reflect multiples of the anticipated
therapeutic exposure under clinical investigation. In the event of poor tolerability in Part
A of this study Part B may be conducted to explore higher doses using titration. Participants
in both Parts A and B will participate in a 9 day wash-out period of current medication
(Study Days 1-9); participants coming into the study on aripiprazole will remain on their
current therapy throughout.